BioSpace News Archive

Unchained Labs, the life sciences company that’s all about getting biologics and gene therapy researchers the right tools for the job, acquired Blacktrace Holdings.

Vistagen today announced new mechanism of action data from a preclinical tissue distribution study in laboratory rats.

DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, will host a conference call and webcast on Thursday, August 3, 2023 at 5:00 p.m. Eastern Time (ET) to discuss the Company’s second-quarter 2023 operating and financial results.

Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it will release its second-quarter 2023 financial results on Tuesday, Aug. 8, 2023, prior to the open of the U.S. financial markets.

Vector Laboratories today announced the acquisition of Quanta BioDesign.

Cognito Therapeutics today announced robust lobe-specific changes in white matter volume and myelination in Alzheimer’s Disease (AD) patients following six-months of non-invasive gamma stimulation therapy using the at-home wearable device.

Elektrofi, a biopharmaceutical formulation technology company focused on leveraging strategic partnerships to revolutionize the delivery of biologic therapies, appointed Victoria Sluzky as Chief Technology Officer.

Adcentrx Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application of ADRX-0706 for the treatment of select advanced solid tumors.

Caeregen Therapeutics announced today that it has been awarded a $1.4 million Phase 2 Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) and National Eye Institute (NEI) to advance the development of CTR-107 (Noregen™), a novel regenerative therapeutic for the treatment of retinal-related vision loss due to a wide range of inherited and age-related diseases.

Devyser’s novel test for detecting donor-derived cell-free DNA in blood samples from kidney-transplant patients and its product for screening and follow-up of stem cell transplanted patients fulfill IVDR requirements in Europe.